Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.68 |
| ▸ | STS | P08842 | 5/20 | 0.65 |
| ▸ | ESR1 | P03372 | 9/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | AR | P10275 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | SNCA | P37840 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712443 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL29643366 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL172746 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL28373123 | 0.90 | SHBG (0.81) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL6695130 | 0.86 | SHBG (0.75) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL5143409 | 0.85 | SHBG (0.74) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL8606752 | 0.84 | SHBG (0.72) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL23027370 | 0.84 | SHBG (0.71) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL2232239 | 0.84 | STS (0.74) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL23645588 | 0.84 | STS (0.74) | SHBGHSD17B1STSESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| US-8003783-B2 | Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer | STERIX LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20100197647-A1 | COMPOUNDS THAT INHIBIT OESTRONE SULPHATASE; COMPOSITIONS THEREOF; AND METHODS EMPLOYING THE SAME | STERIX LIMITED (GB) | 2010-08-05 | — | — | US | disclosed |
| WO-2008147640-A2 | HORMONE REPLACEMENT THERAPY | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080187925-A1 | Biomarkers of Cancer Risk and Their Use in Cancer Detection and Prevention | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2008-08-07 | — | — | US | disclosed |
| US-7342004-B2 | Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds | STERIX LTD. (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7342004-B2 | Thioether sulphamate steroids as steroid inhibitors and anti-cancer compounds | STERIX LTD. (GB) | 2008-03-11 | — | — | US | disclosed |
| US-20070021624-A1 | Steroid sulphatase inhibitors | REED MICHAEL J | 2007-01-25 | — | — | US | disclosed |
| WO-2007008474-A2 | 3 -ESTER PRODRUGS OF ESTRADIOL | WARNER CHILCOTT COMPANY, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021624-A1 | Steroid sulphatase inhibitors | STS, CYP21A2, SULT1E1 | SHBG 56/4885HSD17B1 6/4885STS 1/4885 |
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | SHBG 2/4885HSD17B1 34/4885STS 654/4885 |
| US-20100197647-A1 | COMPOUNDS THAT INHIBIT OESTRONE SULPHATASE; COMPOSITIONS THEREOF; AND METHODS EMPLOYING THE SAME | CYP19A1, SHBG, CYP21A2 | SHBG 2/4885HSD17B1 13/4885STS 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.